These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30699942)

  • 21. Spatial Relationship of Glioma Volume Derived from
    Mauler J; Maudsley AA; Langen KJ; Nikoubashman O; Stoffels G; Sheriff S; Lohmann P; Filss C; Galldiks N; Kops ER; Shah NJ
    J Nucl Med; 2018 Apr; 59(4):603-609. PubMed ID: 28848036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.
    Rossi Espagnet MC; Romano A; Mancuso V; Cicone F; Napolitano A; Scaringi C; Minniti G; Bozzao A
    Br J Radiol; 2016 Oct; 89(1066):20160476. PubMed ID: 27505026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas.
    D'Souza MM; Sharma R; Jaimini A; Panwar P; Saw S; Kaur P; Mondal A; Mishra A; Tripathi RP
    Clin Nucl Med; 2014 Sep; 39(9):791-8. PubMed ID: 25036022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
    Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
    Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
    Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.
    Marner L; Henriksen OM; Lundemann M; Larsen VA; Law I
    Clin Transl Imaging; 2017; 5(2):135-149. PubMed ID: 28936429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
    Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
    Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
    Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
    Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced Imaging Techniques for Radiotherapy Planning of Gliomas.
    Castellano A; Bailo M; Cicone F; Carideo L; Quartuccio N; Mortini P; Falini A; Cascini GL; Minniti G
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool.
    Lopez WO; Cordeiro JG; Albicker U; Doostkam S; Nikkhah G; Kirch RD; Trippel M; Reithmeier T
    Onco Targets Ther; 2015; 8():3803-15. PubMed ID: 26719708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.
    Rachinger W; Goetz C; Pöpperl G; Gildehaus FJ; Kreth FW; Holtmannspötter M; Herms J; Koch W; Tatsch K; Tonn JC
    Neurosurgery; 2005 Sep; 57(3):505-11; discussion 505-11. PubMed ID: 16145529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
    Galldiks N; Kaufmann TJ; Vollmuth P; Lohmann P; Smits M; Veronesi MC; Langen KJ; Rudà R; Albert NL; Hattingen E; Law I; Hutterer M; Soffietti R; Vogelbaum MA; Wen PY; Weller M; Tonn JC
    Neuro Oncol; 2024 Jul; 26(7):1181-1194. PubMed ID: 38466087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET.
    Tsiouris S; Bougias C; Fotopoulos A
    Hell J Nucl Med; 2019; 22(3):206-219. PubMed ID: 31655848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.
    Stadlbauer A; Prante O; Nimsky C; Salomonowitz E; Buchfelder M; Kuwert T; Linke R; Ganslandt O
    J Nucl Med; 2008 May; 49(5):721-9. PubMed ID: 18413402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.